Press Releases

Oasmia Pharmaceutical receives marketing approval for Paclical® in Kazakhstan

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that it has received marketing approval for Paclical in Kazakhst...

Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 28,000,000

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 28,000,000 with an in...

Oasmia Pharmaceutical AB Announces Resignation of its Chief Financial Officer

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology has announced that the Company’s Chief Financial Officer, Fredrik Gynnerstedt, ...

Nexttobe Extends Loan to Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company. The cur...

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) has, as has been previously announced, carried out a rights issue. The shares in the last of the registrations have now b...

Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2017

Oasmia Pharmaceutical AB (publ) held its AGM on Monday, 25 September 2017. The main resolutions passed at the meeting were as follows.   Adoption of balance sheets and profit and lo...

Supplementary proposals of the Nomination Committee for the 2017 Annual General Meeting

For the AGM on September 25, 2017, the Board of Oasmia Pharmaceutical AB has been informed by the company's Nomination Committee of the following. The Nomination Committee proposes that the Board t...

Notification from Oasmia Pharmaceutical AB

Uppsala, Sweden, September 11, 2017 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, hereby issues a notification regarding t...

Oasmia Pharmaceutical AB (publ)

Interim report for the period May – July 2017